Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

Y0000341

Loperamide oxide monohydrate

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

trans-4-(4-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutanamide 1-oxide monohydrate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C29H33ClN2O3 · H2O
Numero CAS:
106900-12-3
Peso molecolare:
511.05
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

loperamide

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

InChI

1S/C29H33ClN2O3/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32(35)20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
KXVSBTJVTUVNPM-UHFFFAOYSA-N

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Loperamide oxide monohydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

1370000

Loperamide hydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1162

Loperamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

L0750000

Loperamide hydrochloride, European Pharmacopoeia (EP) Reference Standard

1370065

Loperamide Related Compound F, United States Pharmacopeia (USP) Reference Standard

BP635

Loperamide hydrochloride, British Pharmacopoeia (BP) Reference Standard

BP636

Loperamide N-oxide, British Pharmacopoeia (BP) Reference Standard

1370010

Loperamide System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

Y0002087

Loperamide for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR9195

4-(4-Chlorophenyl)-4-hydroxypiperidine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR2916

Loperamide Related Compound F, pharmaceutical secondary standard, certified reference material

Pittogrammi

Skull and crossbones
GHS06

Avvertenze

Danger

Indicazioni di pericolo

H301

Classi di pericolo

Acute Tox. 3 Oral

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

K Lavrijsen et al.
Drug metabolism and disposition: the biological fate of chemicals, 23(3), 354-362 (1995-03-01)
Loperamide oxide (LOPOX) is a prodrug of loperamide (LOP). The reduction of LOPOX to LOP was investigated to provide a pharmacokinetic basis for the pharmacodynamics and improved side effect profile of the prodrug. Reduction of LOPOX was studied in vitro
M van Outryve et al.
The Journal of international medical research, 23(5), 335-341 (1995-09-01)
Loperamide oxide was compared with placebo for the treatment of chronic diarrhoea in patients with Crohn's disease. After initially receiving 2 mg loperamide oxide or placebo, hospital out-patients with Crohn's disease were instructed to take one tablet of loperamide oxide
L E Van Beijsterveldt et al.
Drug metabolism and disposition: the biological fate of chemicals, 23(2), 216-222 (1995-02-01)
Loperamide oxide is a prodrug of the effective antidiarrheal loperamide. Administration of this prodrug improves efficacy and tolerability. For better understanding of these effects, the absorption and gastrointestinal distribution of loperamide oxide and of its active drug loperamide were studied.
Treatment of irritable bowel syndrome with loperamide oxide. An open study to determine optimal dosage.
G Ragnarsson et al.
Journal of internal medicine, 248(2), 165-166 (2000-08-18)
F Kamali et al.
European journal of clinical pharmacology, 42(6), 693-694 (1992-01-01)
The pharmacokinetics of loperamide, after oral administration of increasing doses (1 to 16 mg) of loperamide oxide, has been investigated in 10 healthy male volunteers, using a randomised cross-over design. Comparison of the maximum plasma loperamide concentration and AUC demonstrated
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.